Monkeypox in humans: a new outbreak
- PMID: 35785957
- PMCID: PMC9728594
- DOI: 10.37201/req/059.2022
Monkeypox in humans: a new outbreak
Abstract
Infection caused by Monkeypox Virus (MPVX) has small rodents as its natural reservoir and both monkeys and humans are occasional hosts. The causative agent is an Orthopoxvirus (MPVX) that was isolated in monkeys in 1958 and proved capable of passing to humans in 1970. It remained contained in Africa, causing isolated episodes of infection, until 2003 when an outbreak occurred in the United States following importation of animals from that continent. Since then, anecdotal cases have continued to be reported outside Africa, usually very clearly linked to travelers to those countries, but in May 2022, a broad outbreak of this disease has begun, now affecting several continents, with the emergence of human cases of MPVX (H-MPVX) infection mainly among Men that have Sex with Men (MSM). The disease has an incubation time ranging from 5 to 15 days and is characterized by the presence of pustules, fever, malaise and headache. The presence of significant regional lymphadenopathy is a differential feature with episodes of classical smallpox. Proctitis and pharyngitis, with minimal skin lesions, may be another form of presentation. Diagnosis can be confirmed by PCR testing of lesions or by demonstration of MPVX in other body fluids or tissues, although in the appropriate epidemiologic setting the clinical picture is highly suggestive of the disease. Effective drug treatment has been developed as part of programs to protect against potential bioterrorist agents and smallpox vaccinees are known to have high protection against monkeypox. New vaccines are available, but neither the drugs nor the vaccines are yet freely available on the market. The prognosis of the disease appears, at least in adults in developed countries, to be good, with very low mortality figures and much less aggressive behavior than that described in classical smallpox. Isolation measures, essential for the control of the outbreak, have been published by the health authorities.
La infección causada por el Virus de la Viruela del Mono o Monkeypox (MPVX) tiene como reservorio natural los pequeños roedores y tanto el mono como el hombre son huéspedes ocasionales. El agente causal es un Orthopoxvirus (MPVX) que fue aislado en monos en 1958 y se demostró capaz de pasar a humanos en 1970. Se mantuvo contenido en África, causando episodios aislados de infección, hasta el año 2003 en que se produjo un brote en los Estados Unidos tras la importación de animales desde dicho continente. Desde entonces, han seguido comunicándose casos fuera de África, por lo general muy claramente vinculados a viajeros a dichos países, pero en mayo de 2022 se ha iniciado un brote amplio de esta enfermedad que afecta ya a varios continentes, con la aparición de casos humanos de infección por MPVX (H-MPVX) principalmente vinculados a fiestas en las que hay relaciones sexuales de hombres con hombres (HSH). La enfermedad tiene un tiempo de incubación que puede oscilar entre 5 y 15 días y se caracteriza por la presencia de pústulas, fiebre, malestar general y cefalea. La presencia de importantes adenopatías regionales es una característica diferencial con los episodios de viruela clásica. La proctitis y la faringitis, con mínimas lesiones cutáneas, pueden ser otras formas de presentación. El diagnóstico puede confirmarse con una prueba de PCR en las lesiones o con la demostración de MPVX en otros fluidos o tejidos corporales, aunque en el contexto epidemiológico oportuno el cuadro clínico es altamente sugerente de la enfermedad. Hay tratamiento medicamentoso eficaz que ha sido desarrollado como parte de los programas de protección frente a potenciales agentes bioterroristas y se sabe que los vacunados de viruela tienen una protección elevada frente a H-MPVX. Se dispone de nuevas vacunas, pero ni los medicamentos ni las vacunas están todavía libremente disponibles en el mercado. El pronóstico de la enfermedad parece bueno, al menos en países desarrollados y en adultos, con cifras de mortalidad muy bajas y un comportamiento mucho menos agresivo que el descrito en la viruela clásica. Las medidas de aislamiento, imprescindibles para el control del brote, han sido publicadas por las autoridades sanitarias
Keywords: MPVX; Monkeypox; Poxvirus; outbreaks; sexually transmitted infections; smallpox; vaccines.
©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Conflict of interest statement
The authors declare no conflicts of interest
Similar articles
-
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study.Lancet. 2022 Aug 27;400(10353):661-669. doi: 10.1016/S0140-6736(22)01436-2. Epub 2022 Aug 8. Lancet. 2022. PMID: 35952705 Free PMC article.
-
Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis.J Infect Public Health. 2023 Apr;16(4):531-541. doi: 10.1016/j.jiph.2023.02.003. Epub 2023 Feb 9. J Infect Public Health. 2023. PMID: 36801633 Free PMC article. Review.
-
Human monkeypox virus: Epidemiologic review and research progress in diagnosis and treatment.J Clin Virol. 2024 Apr;171:105662. doi: 10.1016/j.jcv.2024.105662. Epub 2024 Feb 28. J Clin Virol. 2024. PMID: 38432097 Review.
-
Monkeypox: A Review.Indian J Pediatr. 2022 Oct;89(10):955-960. doi: 10.1007/s12098-022-04348-0. Epub 2022 Aug 10. Indian J Pediatr. 2022. PMID: 35947269 Free PMC article. Review.
-
Mpox: The Reemergence of an Old Disease and Inequities.Annu Rev Med. 2024 Jan 29;75:159-175. doi: 10.1146/annurev-med-080122-030714. Epub 2023 Oct 3. Annu Rev Med. 2024. PMID: 37788486 Review.
Cited by
-
Monkeypox: Treatment, Vaccination, and Prevention.Cureus. 2023 Jan 6;15(1):e33434. doi: 10.7759/cureus.33434. eCollection 2023 Jan. Cureus. 2023. PMID: 36751201 Free PMC article. Review.
-
The preparedness and knowledge of pharmacists and general practitioners in managing human monkeypox: a highly spreading infectious disease.J Pharm Policy Pract. 2023 Oct 23;16(1):125. doi: 10.1186/s40545-023-00636-y. J Pharm Policy Pract. 2023. PMID: 37872556 Free PMC article.
-
Monkeypox: Emerging virus of concern; antivirals and vaccines therapeutic options.Microb Pathog. 2022 Dec;173(Pt A):105799. doi: 10.1016/j.micpath.2022.105799. Epub 2022 Sep 28. Microb Pathog. 2022. PMID: 36182078 Free PMC article. Review.
-
A review of epidemiology, diagnosis, and management of Mpox: The role of One Health.Glob Health Med. 2025 Feb 28;7(1):1-12. doi: 10.35772/ghm.2024.01072. Glob Health Med. 2025. PMID: 40026855 Free PMC article. Review.
-
Public concerns analysis and early warning of Mpox based on network data platforms-taking Baidu and WeChat as example.Front Public Health. 2025 Mar 5;13:1523408. doi: 10.3389/fpubh.2025.1523408. eCollection 2025. Front Public Health. 2025. PMID: 40109434 Free PMC article.
References
-
- von Magnus P, Andersen EA, Petersen KB, A. B-A. A pox-like disease in cynomolgus monkeys. Acta Path Microbiol Scand. 1958;46:159.
-
- Eke RA. Monkey-pox in a four-year old girl: case report. West Afr Med J Niger Pract. 1972;21(1):21-2. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical